Accro Bioscience
Develops novel therapeutics for immune mediated diseases
$50MSeries C
Role not disclosedSC
Shenzhen Capital Group
Activity from announced rounds
All recorded activity
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $50M 1 disclosed · full round size, not this investor’s share